author-photo

Pablo Morentin Gutierrez

AstraZeneca

28

Papers

326

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Macrophage activation status rather than repolarization is associated with enhanced checkpoint activity in combination with PI3Kg inhibition.

2021 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 5674: Discovery of AZD9833, an oral small molecule selective degrader of the estrogen receptor (SERD)

2020
Show All
- Source
- Cite
- Save
Citations (2)
Abstract 1042: Preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 4369: Preclinical mechanistic PK/PD-efficacy modeling for AZD9833, a novel next generation oral SERD, to support dose selection during early clinical development

2020 Epidemiology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1207: Reversing lactate-driven immunosuppression using the novel, potent and selective MCT4 inhibitor AZD0095

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 100: Novel selective PI3Kγ inhibitor AZD3458 promotes anti-tumor immune responses and reverts resistance to immunotherapy in checkpoint blockade refractory preclinical models

2019 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (2)
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

2018 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (37)
Additional file 8: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

2018
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2641: AZD4635 A2A receptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

2016 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (30)